Cibc World Markets Corp Reduces Position in Eli Lilly and Company (NYSE:LLY)

Cibc World Markets Corp lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 80,414 shares of the company’s stock after selling 5,322 shares during the quarter. Cibc World Markets Corp’s holdings in Eli Lilly and were worth $18,457,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of LLY. Atlas Capital Advisors LLC boosted its stake in shares of Eli Lilly and by 64.6% during the 2nd quarter. Atlas Capital Advisors LLC now owns 107 shares of the company’s stock worth $25,000 after acquiring an additional 42 shares during the last quarter. Cranbrook Wealth Management LLC lifted its stake in shares of Eli Lilly and by 162.3% during the 1st quarter. Cranbrook Wealth Management LLC now owns 181 shares of the company’s stock valued at $34,000 after buying an additional 112 shares in the last quarter. Altshuler Shaham Ltd purchased a new position in shares of Eli Lilly and during the 1st quarter valued at $42,000. HBC Financial Services PLLC purchased a new position in shares of Eli Lilly and during the 1st quarter valued at $46,000. Finally, Corsicana & Co. purchased a new position in shares of Eli Lilly and during the 2nd quarter valued at $46,000. Institutional investors and hedge funds own 81.65% of the company’s stock.

Eli Lilly and stock opened at $233.09 on Wednesday. The company’s 50-day moving average price is $251.93 and its 200-day moving average price is $218.56. Eli Lilly and Company has a twelve month low of $129.21 and a twelve month high of $275.87. The company has a quick ratio of 0.89, a current ratio of 1.15 and a debt-to-equity ratio of 2.21. The company has a market cap of $223.54 billion, a PE ratio of 34.95, a price-to-earnings-growth ratio of 1.86 and a beta of 0.25.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Monday, August 2nd. The company reported $1.87 earnings per share for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.02). Eli Lilly and had a return on equity of 119.12% and a net margin of 22.71%. The business had revenue of $6.74 billion during the quarter, compared to the consensus estimate of $6.59 billion. During the same quarter last year, the firm earned $1.89 earnings per share. The business’s quarterly revenue was up 22.6% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly and Company will post 7.87 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 10th. Investors of record on Friday, August 13th were issued a dividend of $0.85 per share. The ex-dividend date of this dividend was Thursday, August 12th. This represents a $3.40 annualized dividend and a yield of 1.46%. Eli Lilly and’s payout ratio is 42.88%.

LLY has been the topic of a number of analyst reports. Truist Securities lifted their target price on shares of Eli Lilly and from $225.00 to $262.00 and gave the company a “buy” rating in a research note on Friday, July 2nd. Morgan Stanley lifted their target price on shares of Eli Lilly and from $207.00 to $275.00 and gave the company an “overweight” rating in a research note on Wednesday, August 4th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and from $270.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, August 4th. Truist Financial reiterated a “buy” rating and issued a $225.00 price target on shares of Eli Lilly and in a research note on Tuesday, June 8th. Finally, Mizuho boosted their price target on shares of Eli Lilly and from $250.00 to $279.00 and gave the stock a “buy” rating in a research note on Wednesday, August 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Eli Lilly and presently has an average rating of “Buy” and an average target price of $250.41.

In related news, major shareholder Lilly Endowment Inc sold 12,898 shares of the company’s stock in a transaction dated Thursday, June 24th. The shares were sold at an average price of $237.51, for a total transaction of $3,063,403.98. Following the transaction, the insider now directly owns 109,400,402 shares in the company, valued at approximately $25,983,689,479.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 1,044,132 shares of company stock worth $257,735,592 over the last quarter. 0.13% of the stock is currently owned by insiders.

About Eli Lilly and

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

See Also: What is basic economics?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.